We are inspired by a shared vision and mission to save and improve lives.
With a steady focus on innovation and sound science, we work to deliver vaccines, medicines, and animal health products that can help millions around the world.
2019 was a significant year for our company as we executed against our strategic initiatives and drove growth and innovation in the key pillars of oncology, vaccines, hospital and animal health.
We continue to focus our research on conditions that represent some of today’s most significant health challenges—like cancer, HPV, hepatitis C, cardio-metabolic disease, antibiotic-resistant infection and HIV, and we are on the front lines in the fight against emerging global pandemics, such as Ebola.
We also devote extensive time and energy to increasing access to medicines and vaccines through far-reaching programs that donate and deliver our products to the people who need them.
We’re applying our global reach, financial strength and scientific excellence to doing more of what we’re passionate about: improving health and improving lives.
In February 2020, we announced our plan to spin-off our women’s health, trusted legacy brands and biosimilars business into a new company, to be called Organon & Co. The spin-off of Organon will enhance our ability to focus on growth and innovation in our key pillars while allowing Organon to pursue its strategic intent to become a leader in women’s health. The separation of the two companies is expected to provide additional value for patients and shareholders.
As a premier research-intensive biopharmaceutical company, we will continue our pursuit to advance the prevention and treatment of diseases that threaten people and communities around the world. We expect to continue to benefit from strong growth across our current key pillars of Oncology, Vaccines, Hospital and Animal Health, while remaining fully committed to investing in research and development in pursuit of breakthrough innovations across all areas of science and to driving value from our deep late-stage pipeline.
Learn more about how we are better meeting the needs of patients and improving public health globally.
We are a global health care company that delivers innovative health solutions through our prescription medicines, vaccines, biologic therapies and animal health products. View the list of products marketed in the United States.
Our core business is the discovery and development of prescription medicines for diseases and conditions that impact millions of people.
We invest billions of dollars on research to find medicines that can help improve lives.
Vaccines are one of the greatest public health success stories in history, and our company has played its part in that story.
We have been working to discover and develop vaccines for more than a century. Our unique vaccines have helped prevent a number of diseases, including some never thought to be preventable. Today, we remain dedicated to the complex business of researching and producing vaccines.
Our Animal Health business is a global leader in the research, development, manufacturing and sale of veterinary medicines. Our Animal Health business offers a broad choice of vaccines, anti-infective and antiparasitic drugs, a complete range of fertility management products, pharmaceutical specialty products, innovative delivery solutions, performance technologies and value-added programs, such as pet recovery services and livestock data management tools.
In 2019, we completed the acquisition of Antelliq, broadening our Animal Health offerings with digital technologies for both livestock and companion animals, one of the fastest growing segments in the industry.
Our chairman and chief executive officer, Kenneth C. Frazier, is accountable to our company’s Board of Directors.
Learn more about our Board members, including committee charters and assignments.
Our Executive Committee manages the business. These top leaders, representing diverse areas of the company, meet regularly to review progress against our company goals. View the list of Executive Committee members.
The company, Merck & Co., Inc., Kenilworth, N.J., U.S.A., is known as MSD outside the United States and Canada and is listed on the New York Stock Exchange under the symbol “MRK.”
Our pipeline provides an overview of our late-stage clinical development programs and is updated quarterly. View the pipeline.
Today, our company has more than 50 prescription products in key therapeutic areas such as cardiovascular disease, respiratory disease, oncology, neuroscience, infectious disease, immunology and women’s health.